Navigation Links
Indevus Announces Submission of New Drug Application
Date:8/28/2007

y the analysis of the safety measurements collected and the persistence with study treatment. Further, the spectrum of adverse events reported were comparable to other injectable hypogonadism treatments reported in the literature. There were no significant adverse changes in laboratory parameters with NEBIDO treatment.

About NEBIDO

NEBIDO(R) is a long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism. NEBIDO is expected to be the first three-month testosterone preparation available in the U.S. in the growing market for testosterone therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About Hypogonadism

Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone levels can lead to health problems and significantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, muscle loss and weakness, as well as an increased risk of osteoporosis. Today, there are an estimated four to five million men in the U.S. who suffer from hypogonadism. Of this group, less than ten percent are currently receiving treatment with testosterone therapy.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA, for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(R) for bladder c
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
2. Indevus Reports Positive Data From Phase III NEBIDO Trial
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  Dompe, a leader in R&D for new therapeutic ... (Recombinant Human Nerve Growth Factor) has been designated as an ... The candidate drug, developed by the research ... the treatment of neurotrophic keratitis, a degenerative corneal disease that ... is currently without a cure. This is the second orphan ...
(Date:7/23/2014)... 23, 2014  ArmaGen, a privately held biotechnology ... severe neurological disorders, announced today that it has ... with Shire plc to develop AGT-182, an investigational ... both the central nervous system (CNS) and somatic ... MPS II, Hunter syndrome is a rare, severe, ...
(Date:7/23/2014)... 23, 2014 Rolta ... für Sadara Chemical Company (Sadara) erhalten zu ... innerhalb des integrierten Chemiekomplexes von Sadara in ... scope im Wert von mehreren Millionen Dollar ... dar, dessen Wert sich ebenfalls auf mehrere ...
Breaking Medicine Technology:Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
... and SYDNEY, Oct. 27, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenues of $21.3 million for the third quarter ... increase from $13.8 million in revenues for the same ...
Cached Medicine Technology:Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 2HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 3HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 4HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 5HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 6
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative ... come up with alternative means to becoming self-sustaining. ... to accomplish this in the July 17 issue ... (HEX). , “We never expected the operating budgets ... Condeluci, an attorney at the law firm Venable ...
(Date:7/23/2014)... DBC Pri-Med LLC , the leading ... more than 260,000 clinicians and the University of South ... national continuing medical education (CME) curriculum to educate and ... ultrasound and how to utilize these technologies at the ... Carolina School of Medicine will deliver its first education ...
(Date:7/23/2014)... TeraGanix has recently announced the ... located only 4.5 miles off of highway I-8. The new ... accessibility for businesses in the Arizona region that use its ... Its Casa Grande location is only 1 hour away from ... from Phoenix. With over 26 million acres of agricultural ...
(Date:7/23/2014)... VA (PRWEB) July 23, 2014 According ... residential real estate transactions throughout the region, the ... trends in June. Homes are selling quickly throughout the ... parts of the region. The Northern Virginia market includes ... Prince William counties. , The Northern Virginia region saw ...
(Date:7/23/2014)... Townsend Security, a leading authority in data ... security solutions now support two factor authentication. This major ... relying on passwords as their only authentication mechanism. , ... Two Factor Authentication software with the following Alliance ... Alliance AES/400 – High performance, NIST validated AES encryption ...
Breaking Medicine News(10 mins):Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 2Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 3Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 2Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Announces Median Sale Price Increased in the Region in June 2014 2Health News:Townsend Security Brings Two Factor Authentication to Leading IBM i Security Solutions 2
... April 24 Foundation for,Biomedical Research (FBR) Board Chairman ... the highest civilian honor Congress can,bestow, on Wednesday., ... the world of science,are few, but they are iconic ... said President George W. Bush. "Today we gather to ...
... and Employment,Discrimination, BAYSIDE, N.Y., April 24 ... hailed today,s vote in the,United States Senate ... (GINA), to ban genetic discrimination in,health insurance ... GINA,in April 2007., "TSA has worked ...
... First Patient Receives Cimzia(R) Dose through CIMplicity(TM) within Two ... ... April 24 UCB announced today the launch of its,CIMplicity(TM) ... to severe Crohn,s disease. CIMplicity(TM) provides,Cimzia(R) patients and their caregivers ...
... at Long Beach Veterans Administration Hospital, LONG ... Administration will honor Dr. Richard Merkin, President of,Heritage ... of American,war veterans. The VA, in collaboration with ... research study aimed at,examining diabetic ulcers in veterans. ...
... at 11:00,am, Family Research Council will present a lecture ... Health Policy Studies. Mr.,Moffit will discuss why health care ... applications in medicine, e.g. the,right to choose a pro-life ... the life of a loved one. To have these ...
... of Seniors Act, WASHINGTON, April 24 The ... to preventing,unintentional home injuries, applauds today,s enactment of the ... President Bush yesterday, comes,at a critical time when each ... and about 30 percent of those who fall require ...
Cached Medicine News:Health News:Michael E. DeBakey Receives Congressional Gold Medal 2Health News:Tourette Syndrome Association Applauds the Passage of Genetic Information Nondiscrimination Act 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 3Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 4Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 5Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 6Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 7Health News:Veterans Honor Dr. Richard Merkin During Research Week 2Health News:President Signs Elder Falls Bill Into Law 2
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: